| WB | 1/500 - 1/2000 | Human,Monkey |
| IF | 咨询技术 | Human,Monkey |
| IHC | 咨询技术 | Human,Monkey |
| ICC | 1/200 - 1/1000 | Human,Monkey |
| FCM | 1/200 - 1/400 | Human,Monkey |
| Elisa | 1/10000 | Human,Monkey |
| Aliases | IL6ST; GP130; CDW130; IL-6RB |
| Entrez GeneID | 3572 |
| clone | 8D4C5 |
| WB Predicted band size | 103.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Monkey |
| Immunogen | Purified recombinant fragment of human CD130 (AA: extra 73-231) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与CD130(gp130)抗体相关的参考文献摘要，供参考：
---
1. **文献名称**：*Targeting gp130 signaling in inflammatory diseases*
**作者**：Rose-John S. et al.
**摘要**：该综述讨论了gp130(CD130)作为IL-6家族细胞因子的共同信号转导受体，在慢性炎症和癌症中的核心作用。文中总结了针对gp130的单克隆抗体开发进展，包括通过阻断IL-6/gp130信号通路治疗类风湿性关节炎和结肠癌的临床前研究。
---
2. **文献名称**：*Structural basis of gp130 cytokine receptor recognition by therapeutic antibodies*
**作者**：Xu Y. et al.
**摘要**：本研究通过冷冻电镜解析了人源gp130与两种治疗性抗体的复合物结构，揭示了抗体结合gp130的精确表位，为优化靶向gp130的抗体药物(如拮抗剂或激动剂)提供了结构生物学依据。
---
3. **文献名称**：*Antibody-mediated inhibition of the IL-6/gp130 signaling axis reduces tumor burden in murine models of pancreatic cancer*
**作者**：Hegde S. et al.
**摘要**：研究团队开发了一种新型抗gp130抗体，在小鼠胰腺癌模型中通过阻断IL-6信号通路，显著抑制肿瘤生长并降低转移风险，证明了靶向CD130在癌症免疫治疗中的潜力。
---
4. **文献名称**：*Dual targeting of gp130 and STAT3 elicits synergistic antitumor effects in diffuse large B-cell lymphoma*
**作者**：Li H. et al.
**摘要**：该研究结合gp130中和抗体与STAT3抑制剂，在弥漫大B细胞淋巴瘤模型中验证了双重靶向策略的协同效应，为克服IL-6信号通路过度激活相关耐药性提供了新思路。
---
以上文献涵盖基础机制、结构解析及治疗应用，均聚焦CD130抗体的开发或功能研究。如需具体文章链接或补充其他方向，可进一步说明。
CD130. also known as gp130 (glycoprotein 130), is a shared signal-transducing receptor subunit for the interleukin-6 (IL-6) family of cytokines, including IL-6. IL-11. leukemia inhibitory factor (LIF), and oncostatin M (OSM). As a transmembrane glycoprotein, it forms complexes with ligand-specific receptor subunits to activate intracellular signaling pathways, primarily JAK/STAT, MAPK, and PI3K/AKT, which regulate cell proliferation, differentiation, and immune responses. CD130 is ubiquitously expressed in various tissues and plays critical roles in hematopoiesis, inflammation, and cancer progression.
CD130-targeting antibodies are designed to modulate these pathways for therapeutic or research purposes. In therapeutics, anti-CD130 antibodies may block cytokine signaling to treat inflammatory diseases (e.g., rheumatoid arthritis) or cancers where IL-6 family cytokines drive tumor growth and metastasis. Conversely, agonist antibodies can enhance cytoprotective signals in conditions like tissue injury. Research-grade CD130 antibodies are widely used to study cytokine-receptor interactions, signaling mechanisms, and cellular responses in vitro and in vivo. Challenges include balancing specificity (due to shared receptor usage) and managing pleiotropic effects, as CD130 signaling can be both pro- and anti-inflammatory depending on context. Recent studies also explore soluble CD130 isoforms as biomarkers or decoy receptors. Ongoing efforts focus on engineering bispecific antibodies or combining CD130-targeting agents with other therapies to improve efficacy.
×
